Last reviewed · How we verify

John van den Anker — Portfolio Competitive Intelligence Brief

John van den Anker pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Acetaminophen/APAP Acetaminophen/APAP marketed Analgesic and antipyretic Cyclooxygenase (COX), primarily central nervous system isoforms Pain Management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Baxter Healthcare Corporation · 1 shared drug class
  2. Brigham and Women's Hospital · 1 shared drug class
  3. Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina · 1 shared drug class
  4. Hellenic Society of Hematology · 1 shared drug class
  5. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 1 shared drug class
  6. Mallinckrodt · 1 shared drug class
  7. Maoxiang Group Jilin Pharmaceutical Co., Ltd. · 1 shared drug class
  8. Ain Shams University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for John van den Anker:

Cite this brief

Drug Landscape (2026). John van den Anker — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/john-van-den-anker. Accessed 2026-05-14.

Related